TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03672578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no attribution
Description: label with no attribution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No label
Description: No label
Study: NCT02805725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: Trabectedin
Description: Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: Trabectedin
Description: Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Study: NCT03351452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal transcranial direct current stimulation
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real transcranial alternating current stimulation
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
Study: NCT04699734

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine 1%
Description: Nerve block

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9mg/ml
Description: Nerve block
Study: NCT01099163

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tonalin SG1000T FFA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tonalin SG1000T FFA
Study: NCT01493557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: 40 mg q.a.m, p.o.

Intervention type: DRUG
Group type: OTHER
Intervention: Pradaxa (dabigatran etexilate)
Description: 150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pradaxa, within 30 minutes after a meal
Description: Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pradaxa (dabigatran etexilate)
Description: 150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
Study: NCT01910909

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
Study: NCT02656420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout-derived Beverage
Description: Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout-derived Beverage
Description: Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout-derived Beverage
Description: Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo as comparison to broccoli sprout-derived beverages
Study: NCT01062945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching administration of a placebo pill.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
Study: NCT01580280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation
Description: Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust Mobilization and Exercise
Description: Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
Study: NCT01882218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactose
Description: After surgery, galactose will be dripped into the belly for up to 24 hours after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard liver surgery.
Study: NCT03707509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Maximum 6 cycles for combined therapy. Camrelizumab maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study: NCT01332565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 50mg tablet
Study: NCT02772523

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle recommendations
Description: Dietary, and physical, cognitive and social activity recommendations
Study: NCT02513186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study: NCT00659893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical gel
Description: 0.05%, two day dose
Study: NCT03538353

Intervention type: OTHER
Group type: OTHER
Intervention: pain education video
Description: The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
Study: NCT02607553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
Study: NCT01916863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: canagliflozin 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canagliflozin 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: canagliflozin 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Study: NCT03876171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haitian youth family-based intervention study: family functioning
Description: A weekly group therapy with the youth in presence of a parent or caretaker in the family.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haitian youth intervention study: youth psychoeducational
Description: Weekly one and one psychoeducational module will be delivered to the youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haitian family-based intervention study: psychoeducational
Description: Weekly psychoeducational module will be delivered to the adolescent to the youth in the presence of a family.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diversion Programs
Description: Youth will attend individual psychological counselling at an assigned Juvenile Services Department (JSD) diversion program.
Study: NCT00125879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow or 40 mg/kg qow
Study: NCT03218462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment (SADE)
Description: No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment (SADE)
Description: No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
Study: NCT03516851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Precision bypass group
Description: With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
Study: NCT02112435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnyx ®
Description: Active mandibular advancement splint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narval ORM ® or SomnoDent ®
Description: Mandibular advancement splint
Study: NCT01170039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: Lubiprostone will be given as 24 mcg orally twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo pill will be given twice a day for 8 weeks.
Study: NCT03763851

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Active PPP005
Description: Group assigned to active PPP005 in the randomized placebo-controlled trial

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Palliative RadioTherapy to the symptomatic site
Study: NCT03351452

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial electric current stimulation
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
Study: NCT03290885

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined contact aspiration/Stent Retriever Technique
Description: Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent retriever technique
Description: The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter.
Study: NCT01303016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chispuditos
Description: Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
Study: NCT01896219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation station (IMACTIS-CT®)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: Reference method for gestures (carried out under CT) guidance
Study: NCT02648919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noni extract
Description: Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
Study: NCT03252431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: single dose pre-filled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta
Description: single dose pre-filled syringe
Study: NCT02065037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: room temperature air insufflation
Description: control arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: warmed carbon dioxide insufflation
Description: comparator arm
Study: NCT01444612

Intervention type: DRUG
Intervention: dalteparin
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.

Intervention type: DRUG
Intervention: enoxaparin
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.

Intervention type: DRUG
Intervention: fondaparinux
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.

Intervention type: DRUG
Intervention: unfractionated heparin
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
Study: NCT02812342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib ointment
Description: Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
Study: NCT04057950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cosmetic product
Description: Disulfure de sélénium versus placebo formula

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cosmetic product
Description: Disulfure de sélénium versus placebo formula
Study: NCT03337477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate(ZS)
Description: Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose 25g administered IV \<15 minutes before the insulin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Glucose 25g administered IV \<15 minutes before the insulin.
Study: NCT03431207

Intervention type: OTHER
Intervention: Standardized video recording for behaviors
Description: A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded.

Intervention type: OTHER
Intervention: Standardized video recording for behaviors
Description: A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded.

Intervention type: OTHER
Intervention: Standardized video recording for behaviors
Description: A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded.
Study: NCT02202200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD- 0332991
Description: PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients
Study: NCT01857817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-122
Description: The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be prepared to match the active drug.
Study: NCT03763851

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Palliative RadioTherapy to the symptomatic site
Study: NCT00993954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction of Radial Head Subluxation
Description: Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of Radial Head Subluxation
Description: Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
Study: NCT03932825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: An 1-hour session of inhaled nitrous oxide at concentrations of 50%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)
Study: NCT00530868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letrozole (Femara)
Description: Letrozole 2.5 mg PO a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole; Avastin
Description: Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
Study: NCT01990534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin IV infusion